A patient with chronic myeloid leukaemia treated with busulphan for 4.5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. At post-mortem there was minimal leukaemic infiltration but there were alterations in the liver architecture sufficient to explain the portal hypertension. The pathogenesis of the liver changes and their possible relationship to splenomegaly and busulphan toxicity are considered.
Introduction
Portal hypertension in myeloproliferative disorders has been reported in the past (Shaldon and Sherlock, 1962; Blendis et al., 1970b) but only very rarely has this given rise to symptoms, and the pathogenesis is obscure. Sub-clinical portal hypertension has been recorded in seven patients with chronic myeloid leukaemia (Datta et al., 1975) (Fig. 2) ; (e) cholestasis, with bile 'lakes' and dilated canaliculi within lobules and occasionally in bile ducts.
Discussion
Haemodynamic studies in patients with chronic myeloid leukaemia have been carried out in the past (Shaldon and Sherlock, 1962; Blendis et al., 1970b) and increased portal pressure has been found, even in the absence of portal vein thrombosis. Datta et al. (1975) 
